Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy
Leuk Lymphoma
.
2018 Nov;59(11):2757-2761.
doi: 10.1080/10428194.2018.1452215.
Epub 2018 Apr 4.
Authors
Lina van der Straten
1
,
Avinash G Dinmohamed
2
3
4
,
Peter E Westerweel
1
,
Anton W Langerak
5
,
Jurgen Riedl
6
,
Jeanette K Doorduijn
4
,
Arnon P Kater
7
,
Mark-David Levin
1
Affiliations
1
a Department of Internal Medicine , Albert Schweitzer Hospital , Dordrecht , The Netherlands.
2
b Department of Research , Netherlands Comprehensive Cancer Organisation (IKNL) , Utrecht , The Netherlands.
3
c Department of Public Health , Erasmus University Medical Centre , Rotterdam , The Netherlands.
4
d Department of Hematology , Erasmus MC Cancer Institute , Rotterdam , The Netherlands.
5
e Department of Immunology , Erasmus University Medical Centre , Rotterdam , The Netherlands.
6
f Department of Clinical Chemistry , Result laboratories, Albert Schweitzer Hospital , Dordrecht , The Netherland.
7
g Department of Hematology , Academic Medical Centre , Amsterdam , the Netherlands.
PMID:
29616852
DOI:
10.1080/10428194.2018.1452215
No abstract available
Publication types
Letter
Kommentar
MeSH terms
Antibodies, Monoclonal, Murine-Derived
British Columbia
Cyclophosphamide
Humans
Leukemia, Lymphocytic, Chronic, B-Cell*
Rituximab
Substances
Antibodies, Monoclonal, Murine-Derived
Rituximab
Cyclophosphamide